Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO

ZEVRA THERAPEUTICS, INC.

Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.
FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.
MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.
Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.
Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

ZEVRA THERAPEUTICS, INC. reported the full year ended December 31, 2025 results: revenue $106.5 million, net income Net income of $83.2 million, EPS $1.40 per basic and $1.35 per diluted share.

Period: the full year ended December 31, 2025
Revenue: $106.5 million
Net income: Net income of $83.2 million
EPS: $1.40 per basic and $1.35 per diluted share
Result: reported results

Exact text from the filing

--- Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted Company to host conference call and webcast TODAY, March 9, 2026, at 4:30

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.88

ZEVRA THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $34.1 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $34.1 million
Result: reported results

Exact text from the filing

Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Q4 net revenue of $34.1 million

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001434647-26-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.